Anxa1 — Annexin A1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
ANXA1 Gene
| Property | Value |
|----------|-------|
| **Gene Symbol** | ANXA1 |
| **Full Name** | Annexin A1 |
| **Chromosomal Location** | 9q21.13 |
| **NCBI Gene ID** | 303 |
| **OMIM ID** | 151690 |
| **Ensembl ID** | ENSG00000109255 |
| **UniProt ID** | P04083 |
| **Associated Diseases** | Neuroinflammation, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Stroke |
| **Protein Class** | Annexin Family |
| **Molecular Weight** | ~37 kDa |
ANXA1 (Annexin A1), also known as lipocortin-1, is a calcium-dependent phospholipid-binding protein belonging to the annexin family. Originally discovered as a glucocorticoid-regulated protein with anti-inflammatory properties, ANXA1 has emerged as a critical regulator of neuroinflammation, neuronal survival, and glial cell function. Its expression in the central nervous system makes it a key player in neurodegenerative disease pathogenesis and a potential therapeutic target.
The ANXA1 gene is located on chromosome 9q21.13 and consists of 13 exons encoding a protein of 346 amino acids. The gene promoter contains responsive elements for glucocorticoids, NF-κB, and other transcription factors, allowing dynamic regulation in response to inflammatory signals.
ANXA1 performs diverse cellular functions:
- Inhibits phospholipase A2 activity
- Reduces eicosanoid production
- Blocks neutrophil adhesion and migration
- Modulates cytokine release from immune cells
- Calcium-dependent membrane organization
- Phospholipid vesicle trafficking
- Exocytosis regulation
- Cytoskeletal interactions
- Promotes neuronal survival
- Modulates glial cell function
- Regulates neuroinflammation
- Supports blood-brain barrier integrity
ANXA1 is widely expressed in the nervous system:
In the brain, ANXA1 is particularly abundant in the hippocampus, cortex, and basal ganglia, regions affected in neurodegenerative diseases.
ANXA1 plays complex roles in AD:
- Amyloid-beta regulation: Modulates Aβ production and aggregation
- Neuroinflammation: Both pro- and anti-inflammatory effects
- Neuronal protection: Reduces tau phosphorylation
- Therapeutic target: Annexin A1 mimetic peptides in development
- Protects dopaminergic neurons
- Modulates microglial activation
- May reduce α-synuclein toxicity
- Altered expression in PD brain
- Regulatory role in demyelination
- Modulates autoimmune responses
- Affects oligodendrocyte survival
- Potential therapeutic target
¶ Stroke and Ischemia
- Provides neuroprotection in acute stroke
- Reduces infarct size
- Anti-apoptotic effects
- Blood-brain barrier protection
ANXA1 is a key regulator of neuroinflammation:
- Microglial activation state
- Cytokine and chemokine production
- T-cell trafficking
- Astrocyte reactivity
ANXA1 acts through:
- Formyl Peptide Receptor (FPR): G-protein coupled receptor mediating anti-inflammatory signals
- EGFR Transactivation: Growth factor signaling
- S1PR1: Sphingosine-1-phosphate receptor interactions
- Phospholipase inhibition: Reduces pro-inflammatory lipid mediators
- ERK/MAPK modulation: Cell survival signaling
- NF-κB pathway: Inflammatory gene expression
- Cellular migration: Leukocyte trafficking
- S100A11 (S100 calcium-binding protein)
- Annexin A2 (heterotetramer formation)
- Glucocorticoid receptor
- FPR receptors
ANXA1-targeting strategies include:
- ANXA1 mimetic peptides: Ac2-26 and derivatives
- FPR agonists: Synthetic formyl peptide analogs
- Antibodies: Anti-ANXA1 for autoimmune conditions
- Gene therapy: AAV-mediated ANXA1 expression
- Stroke: Phase II trials with ANXA1 peptides
- Neurodegeneration: Preclinical studies ongoing
- Autoimmune disorders: Immunomodulation
- Pain management: ANXA1 analogs for analgesia
| Model |
Findings |
| ANXA1 Knockout Mice |
Exaggerated inflammation, increased disease severity |
| Transgenic ANXA1 |
Reduced neuroinflammation, neuroprotection |
| FPR2/ALX Knockout |
Loss of ANXA1 anti-inflammatory effects |
| Stroke Models |
ANXA1 reduces infarct size 40-60% |
The study of Anxa1 — Annexin A1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.